DailyDoctor Archive Specialties Get app
All urology briefings

The edition · Urology

After a negative prostate MRI, PSA density sorted who needed another look

In Göteborg-2, men with PSA density below 0.10 had less than half the seven-year risk of significant cancer after a clear MRI; a membranous urethral length model predicted near-continence but not pad-free continence; and a local-anaesthetic device handled small bladder recurrences in clinic.

The edition in brief

A pre-specified analysis of the Göteborg-2 screening trial followed 1685 men with a negative initial prostate MRI for a median 5.5 years. Seven-year cumulative incidence of clinically significant cancer was 5.5% with PSA density below 0.10 ng/mL², against 13.8% and 11.9% at higher densities; a follow-up strategy triggering repeat MRI only at density 0.10 or above was modelled to cut MRI use by 60% and biopsies by 46%, at the cost of delaying 17% of significant diagnoses. An external validation in 500 men found a continence model using MRI membranous urethral length was useful for predicting 0–1 pad a day after prostatectomy (C-statistic 0.69) but not pad-free continence (0.64, poor calibration). A French retrospective study of 442 patients found clinical variables predicted stone composition with a macro-AUC of 0.81, rising to 0.98 once stone morphology was added. A first-in-human study of 18 patients with small recurrent bladder tumours found an all-in-one outpatient device under local anaesthesia gave evaluable biopsies in 92% with no complications. Today's pearl covers the obstructed, infected kidney.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free